11q13 is a susceptibility locus for hormone receptor positive breast cancer.
Lambrechts D., Truong T., Justenhoven C., Humphreys MK., Wang J., Hopper JL., Dite GS., Apicella C., Southey MC., Schmidt MK., Broeks A., Cornelissen S., van Hien R., Sawyer E., Tomlinson I., Kerin M., Miller N., Milne RL., Zamora MP., Pérez JIA., Benítez J., Hamann U., Ko Y-D., Brüning T., GENICA Network None., Chang-Claude J., Eilber U., Hein R., Nickels S., Flesch-Janys D., Wang-Gohrke S., John EM., Miron A., Winqvist R., Pylkäs K., Jukkola-Vuorinen A., Grip M., Chenevix-Trench G., Beesley J., Chen X., Investigators kConFab None., Australian Ovarian Cancer Study Group None., Menegaux F., Cordina-Duverger E., Shen C-Y., Yu J-C., Wu P-E., Hou M-F., Andrulis IL., Selander T., Glendon G., Mulligan AM., Anton-Culver H., Ziogas A., Muir KR., Lophatananon A., Rattanamongkongul S., Puttawibul P., Jones M., Orr N., Ashworth A., Swerdlow A., Severi G., Baglietto L., Giles G., Southey M., Marmé F., Schneeweiss A., Sohn C., Burwinkel B., Yesilyurt BT., Neven P., Paridaens R., Wildiers H., Brenner H., Müller H., Arndt V., Stegmaier C., Meindl A., Schott S., Bartram CR., Schmutzler RK., Cox A., Brock IW., Elliott G., Cross SS., Fasching PA., Schulz-Wendtland R., Ekici AB., Beckmann MW., Fletcher O., Johnson N., Silva IDS., Peto J., Nevanlinna H., Muranen TA., Aittomäki K., Blomqvist C., Dörk T., Schürmann P., Bremer M., Hillemanns P., Bogdanova NV., Antonenkova NN., Rogov YI., Karstens JH., Khusnutdinova E., Bermisheva M., Prokofieva D., Gancev S., Jakubowska A., Lubinski J., Jaworska K., Durda K., Nordestgaard BG., Bojesen SE., Lanng C., Mannermaa A., Kataja V., Kosma V-M., Hartikainen JM., Radice P., Peterlongo P., Manoukian S., Bernard L., Couch FJ., Olson JE., Wang X., Fredericksen Z., Alnaes GG., Kristensen V., Børresen-Dale A-L., Devilee P., Tollenaar RAEM., Seynaeve CM., Hooning MJ., García-Closas M., Chanock SJ., Lissowska J., Sherman ME., Hall P., Liu J., Czene K., Kang D., Yoo K-Y., Noh D-Y., Lindblom A., Margolin S., Dunning AM., Pharoah PDP., Easton DF., Guénel P., Brauch H.
A recent two-stage genome-wide association study (GWAS) identified five novel breast cancer susceptibility loci on chromosomes 9, 10, and 11. To provide more reliable estimates of the relative risk associated with these loci and investigate possible heterogeneity by subtype of breast cancer, we genotyped the variants rs2380205, rs1011970, rs704010, rs614367, and rs10995190 in 39 studies from the Breast Cancer Association Consortium (BCAC), involving 49,608 cases and 48,772 controls of predominantly European ancestry. Four of the variants showed clear evidence of association (P ≤ 3 × 10(-9) ) and weak evidence was observed for rs2380205 (P = 0.06). The strongest evidence was obtained for rs614367, located on 11q13 (per-allele odds ratio 1.21, P = 4 × 10(-39) ). The association for rs614367 was specific to estrogen receptor (ER)-positive disease and strongest for ER plus progesterone receptor (PR)-positive breast cancer, whereas the associations for the other three loci did not differ by tumor subtype.